ANGPT2

Across TCGA pan-cancer cohorts, ANGPT2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANGPT2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANGPT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANGPT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ANGPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.288	0.727	.003	32	view →
LUAD	OS	Tertile	III,IV	0.350	0.875	.002	19	view →
CCRCC	DFS	Median	All	0.466	0.970	.001	16	view →
UCEC	OS	Tertile	III,IV	0.884	0.365	.013	8	view →
GBM	DFS	Tertile	All	0.877	0.618	.009	5	view →
LSCC	DFS	Tertile	All	1.000	0.653	.018	5	view →
HNSC	OS	Median	II,III,IV	0.576	0.755	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANGPT2–PDAC (DFS)

Open the PDAC breakdown →